Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles

Journal of Infectious Diseases

Volumn 201, Issue 2, 2010, Pages 190-198

  Kim, Yeu Chun ^a   Quan, Fu Shi ^b   Yoo, Dae Goon ^b   Compans, Richard W ^b   Kang, Sang Moo ^b   Prausnitz, Mark R ^a  

^a Georgia Institute of Technology   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INFLUENZA VACCINE; TREHALOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CADAVER; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE MICROSCOPY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MICRONEEDLE PATCH; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SINGLE DRUG DOSE; ANIMAL; BAGG ALBINO MOUSE; EQUIPMENT DESIGN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INSTRUMENTATION; INTRADERMAL DRUG ADMINISTRATION; ORTHOMYXOVIRUS INFECTION;

ANIMALS; ANTIBODY FORMATION; EQUIPMENT DESIGN; FEMALE; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 75649140606     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/649228     Document Type: Article

References (36)

1. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004; 59: 1-15. (Pubitemid 38186834)
2. Palese P. Influenza: old and new threats. Nat Med 2004; 10: S82-7.
3. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57: 1-60.
4. Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of bloodborne viruses. Health Promot Int 2004; 19: 95-103. (Pubitemid 38364808)
5. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005; 5: 905-916
6. Levine MM. Can needle-free administration of vaccines become the norm in global immunization? Nat Med 2003; 9: 99-103.
7. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351: 2286-2294 (Pubitemid 39552744)
8. Glenn GM, Taylor DN, Li XR, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000; 6: 1403-1406 (Pubitemid 32001027)
9. Kenney RT, Freeh SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351: 2295-2301 (Pubitemid 39552745)
10. Laurent PE, Bonnet S, Aichas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007; 25: 8833-8842 (Pubitemid 350192056)
11. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002; 8: 415-419
12. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004; 56: 581-587
13. Widera G, Johnson J, Kim L, et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 2006; 24: 1653-1664 (Pubitemid 43238242)
14. Bal SM, Caussin J, Pavel S, Bouwstra JA. In vivo assessment of safety of microneedle arrays in human skin. Eur J Pharm Sci 2008; 35: 193-202.
15. Gill HS, Denson DD, Burris BA, Prausnitz MR. Effect of microneedle design on pain in human volunteers. Clin J Pain 2008; 24: 585-594
16. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27: 454-459
17. Zhu QY, Zarnitsyn VG, Ye L, et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A 2009; 106: 7968-7973
18. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE 2009; 4: e4773.
19. Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 2008; 82: 1350-1359
20. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release 2007; 117: 227-237
21. Quan FS, Yoo DG, Song JM, Clements JD, Compans RW, Kang SM. Kinetics of immune responses to influenza virus-like particles and dosedependence of protection with a single vaccination. J Virol 2009; 83: 4489-4497
22. Slifka MK, Matloubian M, Ahmed R. Bone-marrow is a major site of long-term antibody-production after acute viral infection. J Virol 1995; 69: 1895-1902
23. Quan FS, Huang CZ, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007; 81: 3514-3524 (Pubitemid 46456660)
24. Azzi L, El-Alfy M, Martel C, Labrie F. Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone. J Invest Dermatol 2005; 124: 22-27 (Pubitemid 40100944)
25. Van Reeth K. Cytokines in the pathogenesis of influenza. Vet Microbiol 2000; 74: 109-116
26. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4: 211-222 (Pubitemid 38339087)
27. Hauge S, Madhun A, Cox RJ, Haaheim LR. Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clin Vaccine Immunol 2007; 14: 978-983
28. Guebre-Xabier M, Hammond SA, Epperson DE, Yu JM, Ellingsworth L, Glenn GM. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J Virol 2003; 77: 5218-5225
29. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
30. Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 1987; 165: 64-69
31. Klaus GG, Pepys MB, Kitajima K, Askonas BA. Activation of mouse complement by different classes of mouse antibody. Immunology 1979; 38: 687-695 (Pubitemid 10145294)
32. Nimmerjahn F, Ravetch JV Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005; 310: 1510-1512 (Pubitemid 41746349)
33. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 2004; 199: 227-250 (Pubitemid 38736775)
34. Richards S, Watanabe C, Santos L, Craxton A, Clark EA. Regulation of B-cell entry into the cell cycle. Immunol Rev 2008; 224: 183-200.
35. De Becker G, Somasse T, Nabavi N, et al. Immunoglobulin isotype regulation by antigen-presenting cells in-vivo. Eur J Immunol 1994; 24: 1523-1528 (Pubitemid 24203755)
36. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedlebased vaccines. Curr Top Microbiol Immunol 2009; 333: 369-393